Safety Platform for Emergency vACcines (SPEAC)

Over 8 million lives. That is the number of people who might be alive today if the international community had accomplished the #100DaysMission to develop safe and effective new vaccines against SARS-CoV-2 in three months. ➡️https://lnkd.in/ejxcN8db   This finding is highlighted in new research conducted by modelling experts at Imperial College London’s MRC Centre for Global Infectious Disease Analysis, published today in The Lancet Global Health.    Crucially, the researchers found that a successful #100DaysMission response to COVID-19’s emergence would have had by far its greatest impact on the lives and livelihoods of people in the Global South. In lower middle-income countries, the 100 Days Mission could have: 🦠Prevented 800 million COVID-19 infections  🏥Averted 15.7 million COVID-19 hospitalisations  🫂Saved 4.8 million lives    Assessing the potential economic impact of the 100 Days Mission, the researchers estimated that the 8.3 million lives saved would represent a monetary saving of as much as $14.3 trillion based on the value of statistical life years. In addition, they estimate that productivity losses due to illness amounting to almost $1.4 trillion and $63 billion of hospitalisation costs would have been averted globally.    The 100 Days Mission, spearheaded by CEPI, is a global health security plan for the world to be able to develop and make available new vaccines against a future pathogen with pandemic potential within 100 days of that pandemic threat being recognised. 100 days is around a third of the time it took the world to deliver the first safe, effective COVID-19 vaccines after SARS-CoV-2 began spreading.    🔊Press release available here – https://lnkd.in/ejxcN8db 📄Read the full study here (🔓) – https://lnkd.in/ecnixG7w  👩🔬Learn more about the 100 Days Mission – https://lnkd.in/e8ppxChU

Last week, SPEAC members shared insights at the poster presentation of the 23rd International Society of Pharmacovigilance (ISoP Online) conference. This year’s topic was “Global Perspectives on Pharmacovigilance in Digital Age and Advanced Therapeutics”.    During the poster presentation, Esperança Sevene and Andy Stergachis presented a poster titled 'Landscape Assessment of Active Safety Surveillance of Novel Vaccines in Low- and Middle-Income Countries.' Additionally, Eileen Farnon presented on 'Preparing for Vaccine Adverse Events of Special Interest-X (AESI-X): A Standardized Approach Applied to Novel Vaccines.'    🌐 Aligned with the theme of ISoP’s annual conference on the digital era, sharing knowledge about Adverse Events of Special Interest (AESI) has become increasingly important. We invite you to explore our latest AESI list for vaccines aimed at preventing #Mpox: https://lnkd.in/dUY4_yyX 

Last week, Safety Platform for Emergency vACcines (SPEAC) and CEPI (Coalition for Epidemic Preparedness Innovations) members participated in the 23rd annual conference of the International Society of Pharmacovigilance (ISoP Online) in Montreal focused on "Global Perspectives on Pharmacovigilance in the Digital Age and Advanced Therapeutics." Chaired by CEPI (Coalition for Epidemic Preparedness Innovations)’s Rebecca Chandler, the Plenary session “Preparedness for the next disaster” discussed important vaccine safety and evidence generation aspects. Eileen Farnon from Safety Platform for Emergency vACcines (SPEAC) and the Brighton Collaboration discussed tools and guidance to support the efficient and robust generation of safety evidence. Bruce Carleton highlighted the role of genomics in understanding vaccine safety, while Danielle Craig emphasized regulatory preparedness to generate strong evidence for vaccines during public health emergencies. Alexander Precioso focused on the importance of building pharmacovigilance capacity among vaccine manufacturers in the Global South. Additionally, two research abstracts were presented: one on adverse events following COVID-19 vaccinations in South Africa by Kimberley Gutu, and another on tinnitus cases after COVID-19 vaccinations in Sweden by Anders Sundström. 🌐 Aligned with the theme of ISoP’s annual conference on the digital era, sharing knowledge about Adverse Events of Special Interest (AESI) has become increasingly important. We invite you to explore our latest AESI list for vaccines aimed at preventing Marburg Virus Disease: https://lnkd.in/e5WGisf7

⚕️Our AESI list V 1.0 for Marburg is available here:   https://lnkd.in/eYKfse4v 📋 The list is open to comment. Please share your input with bc-coordinator@taskforce.org. 🗓️ We will update the list on an ongoing basis. #VaccineSafety CEPI (Coalition for Epidemic Preparedness Innovations) Global Vaccine Data Network – GVDN VAC4EU - Vaccine Monitoring Collaboration for Europe International Network of Special Immunization Services - INSIS   #MarburgVirus #PublicHealth

Visit our page for #VaccineSafety Resources for #Mpox to access our CEM protocol, AESI list, CEM questionnaires, and more: https://lnkd.in/e8EXnvH8 We will add more tools to this page as they become available.

Now available on our Zenodo site: Cohort event monitoring (CEM) Protocol Template for active safety surveillance after vaccination with #mpox vaccines https://lnkd.in/e9pu4RDV #VaccineSafefty

We have updated the AESI list for #mpox. Access it on our site here: https://lnkd.in/dUY4_yyX #VaccineSafety

The National Institutes of Health releases #mpox research agenda: Plan will advance knowledge of virus biology to improve detection, treatment and prevention. https://lnkd.in/eUUnStna

The latest World Health Organization situation report for the multi-country outbreak of #mpox is now available: https://lnkd.in/ezW6hJxP

The World Health Organization prequalifies the first vaccine against #mpox: https://lnkd.in/dFDVzmqw The World Health Organization (WHO) has announced the MVA-BN vaccine as the first vaccine against mpox to be added to its prequalification list. The prequalification approval is expected to facilitate timely and increased access to this vital product in communities with urgent need, to reduce transmission and help contain the outbreak. WHO’s assessment for prequalification is based on information submitted by the manufacturer, Bavarian Nordic A/S, and review by the European Medicines Agency, the regulatory agency of record for this vaccine.